Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Sartorius Bia Separations D O O currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This count of 2 pending office actions represents the active workload for the company as it seeks to protect its separation and purification technologies. In the Biotechnology & Pharmaceuticals sector, these filings often require detailed technical arguments to overcome prior art rejections during examination.
The prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. Having only 1 distinct examiner means the company must focus its strategy on the specific review style of a single individual. The presence of 1 distinct art unit indicates that the applications are classified within a very specific technical division of the patent office, rather than spanning multiple disciplines.
SIFFORD, JEFFREY MARK is the busiest examiner for this portfolio, currently handling 2 pending office actions. Because 2 pending office actions are assigned to this specific examiner, the entire pending portfolio is subject to their individual review style and historical allowance rates. The 2 pending office actions in the total portfolio are equal to the 2 pending office actions assigned to SIFFORD, JEFFREY MARK, indicating a high concentration of examiner risk.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIFFORD, JEFFREY MARK | 2 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007823 | ENHANCED PURIFICATION OF ADENO-ASSOCIATED VIRUS TO MORE EFFECTIVELY REMOVE CONTAMINATING DNA | SIFFORD, JEFFREY MARK | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007823 | ENHANCED PURIFICATION OF ADENO-ASSOCIATED VIRUS TO MORE EFFECTIVELY REMOVE CONTAMINATING DNA | SIFFORD, JEFFREY MARK | 26d |
| 17800592 | A METHOD FOR SEPARATION OR DEPLETION OF EMPTY AAV CAPSIDS FROM FULL AAV CAPSIDS | SIFFORD, JEFFREY MARK | 30d |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18007823 | ENHANCED PURIFICATION OF ADENO-ASSOCIATED VIRUS TO MORE EFFECTIVELY REMOVE CONTAMINATING DNA | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | 26d | Pending | Dec 02, 2022 |
| 17800592 | A METHOD FOR SEPARATION OR DEPLETION OF EMPTY AAV CAPSIDS FROM FULL AAV CAPSIDS | SIFFORD, JEFFREY MARK | 1671 | §103 | Final Rejection | 30d | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSartorius Bia Separations D O O has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jeffrey Mark Sifford has the most, with 2 of Sartorius Bia Separations D O O's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
